A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, Verma A.
Goldfinger M, et al. Among authors: feldman ej.
Blood. 2024 Sep 24:blood.2024025834. doi: 10.1182/blood.2024025834. Online ahead of print.
Blood. 2024.
PMID: 39316768